This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adam, R. M. Articles by Freeman, M. R. Search for Related Content PubMed PubMed Citation Articles by Adam, R. M. Articles by Freeman, M. R.

A Nuclear Form of the Heparin-binding Epidermal Growth Factor-like Growth Factor Precursor Is a Feature of Aggressive Transitional Cell Carcinoma¹

Departments of Urology and Surgery [R. M. A., T. D., D. L. M., J. G. B., J. L., M. R. F.] and Orthopedic Surgery [D. Z.], Children’s Hospital Boston and Harvard Medical School, Boston, Massachusetts 02115; Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115 [M. H. W.]; Cancer Research Unit, University of Newcastle upon Tyne, Newcastle NE2 4HH, United Kingdom [P. H. R.]; and Division of Urology, University of Leicester, Leicester LE5 4PW, United Kingdom [J. K. M.]

Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the ErbB receptor ligand family, exists in distinct molecular forms with disparate biological activities. Previous studies have shown that the HB-EGF precursor, proHB-EGF, localizes to the cytoplasm of transitional cells of the human bladder urothelium and that the soluble form of the growth factor is an autocrine urothelial cell mitogen. In this study, we identify a potential role for proHB-EGF in transitional cell carcinoma (TCC) of the bladder. In an analysis of 33 TCC specimens and 8 normal controls, proHB-EGF, identified using an antibody directed against the cytoplasmic tail domain, localized to cell nuclei in a manner that correlated positively with tumor stage and grade (P < 0.001). The ability of proHB-EGF to localize to the nucleus was independently confirmed in a TCC cell line (TCCSUP), in which 40% of transfected proHB-EGF was found to reside in the nuclear compartment. In Kaplan-Meier survival analysis, TCC patients with >20% proHB-EGF-positive cell nuclei demonstrated markedly reduced survival compared with patients with <20% proHB-EGF-positive nuclei (P < 0.005, log-rank test). In multivariate analysis, nuclear localization of proHB-EGF of >20% was an independent prognostic indicator of disease-specific mortality. This is the first report in any cell type that HB-EGF is capable of translocating to the cell nucleus. In addition, our findings suggest that nuclear proHB-EGF may play a role in disease progression in bladder cancer and possibly other cancers.

This article has been cited by other articles:

				J. Kim, W. J. Jahng, D. Di Vizio, J. S. Lee, R. Jhaveri, M. A. Rubin, A. Shisheva, and M. R. Freeman The Phosphoinositide Kinase PIKfyve Mediates Epidermal Growth Factor Receptor Trafficking to the Nucleus Cancer Res., October 1, 2007; 67(19): 9229 - 9237. [Abstract] [Full Text] [PDF]

				C. C. Lynch, T. Vargo-Gogola, M. D. Martin, B. Fingleton, H. C. Crawford, and L. M. Matrisian Matrix Metalloproteinase 7 Mediates Mammary Epithelial Cell Tumorigenesis through the ErbB4 Receptor Cancer Res., July 15, 2007; 67(14): 6760 - 6767. [Abstract] [Full Text] [PDF]

				M. Breuleux, F. Schoumacher, D. Rehn, W. Kung, H. Mueller, and U. Eppenberger Heregulins Implicated in Cellular Functions Other Than Receptor Activation Mol. Cancer Res., January 1, 2006; 4(1): 27 - 37. [Abstract] [Full Text] [PDF]

				J. Kim, R. M. Adam, and M. R. Freeman Trafficking of Nuclear Heparin-Binding Epidermal Growth Factor-like Growth Factor into an Epidermal Growth Factor Receptor-Dependent Autocrine Loop in Response to Oxidative Stress Cancer Res., September 15, 2005; 65(18): 8242 - 8249. [Abstract] [Full Text] [PDF]

				D. R. McCulloch, P. Akl, H. Samaratunga, A. C. Herington, and D. M. Odorico Expression of the Disintegrin Metalloprotease, ADAM-10, in Prostate Cancer and Its Regulation by Dihydrotestosterone, Insulin-Like Growth Factor I, and Epidermal Growth Factor in the Prostate Cancer Cell Model LNCaP Clin. Cancer Res., January 1, 2004; 10(1): 314 - 323. [Abstract] [Full Text] [PDF]